Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Profound Medical (NASDAQ:PROF) will showcase TULSA-PRO, the TULSA Procedure and iMRI prostate ablation at AUA2026 in Washington, DC. Four oral presentations will cover MRI-guided transurethral ultrasound ablation outcomes, safety and real‑world data in localized prostate cancer.
The company will demonstrate TULSA-PRO and a Siemens MAGNETOM Free.Max MR at Booth #413 and is launching an initiative to explore integrating PSMA PET molecular imaging into TULSA-PRO treatment planning to support intent-to-treat decisions and patient monitoring.
Profound Medical (NASDAQ: PROF) reported voting results from its May 13, 2026 Annual General and Special Meeting. Shareholders representing 25,347,133 shares, or 69.754% of outstanding shares, were present. All matters in the April 2, 2026 circular were approved, including eight director elections, auditor appointment, and long-term incentive plan resolutions.
Profound Medical (NASDAQ:PROF) reported Q1 2026 revenue of approximately $5.3M, up 104% YoY, with recurring non-capital revenue of $2.5M and capital equipment revenue of $2.9M. Gross margin was 72%, operating expenses were $11.8M, and net loss narrowed to $7.0M ($0.19/share).
The company ended Q1 with $50.3M cash, a TULSA-PRO installed base of 80 systems, shipment of six systems, and announced Humana coverage adding ~6.9M covered lives; full-year 2026 revenue guidance is ~$25M.
Danaher (NYSE: DHR), Medtronic (NYSE: MDT), DexCom (NASDAQ: DXCM), Profound Medical (NASDAQ: PROF) and VentriPoint Diagnostics (TSXV: VPT / OTCPK: VPTDF) are highlighted in a sector overview of rising AI diagnostics investment.
Key facts: Danaher reported Q1 2026 revenue of $6.0B (+3.5% YoY) and adjusted diluted EPS $2.06 (+9.5%), raised FY2026 EPS guide to $8.35–$8.55. Medtronic closed a $585M CathWorks deal. VentriPoint won a Gold Edison Award and holds US/Canada/Europe approvals for VMS+ 4.0.
Profound Medical (NASDAQ:PROF) will report its First Quarter 2026 financial results after market close on May 7, 2026.
Management will host a conference call at 4:30 p.m. ET the same day to review results and business developments. Live dial-in numbers and a webcast archive will be available for investors.
Profound Medical (NASDAQ:PROF) announced management will present an update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026 at 10:00 a.m. ET at the Metro Toronto Convention Centre.
The presentation will be broadcast live and archived on the company website under the Investors IR Calendar.
Profound Medical (NASDAQ:PROF) announced that its TULSA-PRO MRI-guided, incision-free prostate therapy will be featured in multiple presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting in Toronto, April 11-15, 2026.
Highlights include five oral talks on April 12 and additional sessions on April 13 showcasing CAPTAIN trial data, systematic reviews, and automation advances in MRI-guided prostate ablation.
Profound Medical (NASDAQ:PROF) congratulated Texas Prostate and Dr. James Cochran for completing their 100th TULSA Procedure at Dallas Medical Center on March 27, 2026. Texas Prostate reported a 500% increase in TULSA volumes after shifting from private-pay to a Medicare collaboration, expanding patient access.
The TULSA Procedure uses the TULSA-PRO system with MRI-guided, robotic directional ultrasound and real-time thermography to ablate prostate tissue with precise temperature control.
Profound Medical (NASDAQ:PROF) reported that the randomized CAPTAIN trial met its prespecified primary safety endpoint: preservation of erectile function and urinary continence at 6 months favored the TULSA Procedure 50% vs robotic radical prostatectomy (RP) 24% (p<0.05, RR 2.1).
CAPTAIN enrolled 211 patients across 23 sites. Key benefits after TULSA included 84% pad-free continence, 56% erectile function, zero median blood loss, shorter hospital stay, fewer hospitalizations (0.7% vs 6.3%), and faster return to work. 12-month TULSA oncologic data are pending.
Profound Medical (NASDAQ:PROF) announced that the first clinical outcomes from the Level 1 post‑market CAPTAIN trial comparing the TULSA Procedure with robotic radical prostatectomy will be presented at EAU 2026 on March 13, 2026 at 9:40 a.m. EDT.
Profound will issue a follow-up press release and host an investor webinar at 11:30 a.m. EDT on March 13 where Dr. Laurence Klotz will review CAPTAIN data; management will also hold one‑on‑one meetings at the ROTH Conference March 22–24, 2026 in Dana Point, CA.